Previous 10 | Next 10 |
Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Continued focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) Presented new, positive data from Phase 2 REVIVE study of rusfertide in PV at the...
The following slide deck was published by Protagonist Therapeutics, Inc. in conjunction with this event. For further details see: Protagonist Therapeutics (PTGX) Presents At Jefferies Healthcare Conference - Slideshow
Protagonist has recently faced a number of mishaps. These make the stock risky. They have a good deal of cash for now. For further details see: Protagonist: Too Many Red Flags
Gainers: Okta (OKTA) +14%. StoneCo (STNE) +9%. Nurix Therapeutics (NRIX) +5%. Protagonist Therapeutics (PTGX) +5%. MacroGenics (MGNX) +5%. Losers: HashiCorp (HCP) -9%. JOANN (JOAN) -8%. Instil Bio (TIL) -5%. Magnite (MGNI) -5%. Zumiez (ZUMZ) -4%. For further details se...
Gainers: Repare Therapeutics (RPTX) +20%. Credo Technology Group Holding (CRDO) +8%. Elevation Oncology (ELEV) +8%. MongoDB (MDB) +6%. Global Blood Therapeutics (GBT) +5%. Losers: Charge Enterprises (CRGE) -5%. NerdWallet (NRDS) -5%. Protagonist Therapeutics (PTGX) -5%. ...
Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference PR Newswire NEWARK, Calif. , June 1, 2022 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Pat...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have never really managed to recreate the success they had in 2020 amid the Covid-19 outbreak. For a second year in running, the sector is caught in a rut, underperforming the beaten-down broader market. Th...
The following slide deck was published by Protagonist Therapeutics, Inc. in conjunction with this event. For further details see: Protagonist Therapeutics (PTGX) Presents at Digestive Disease Week (DDW) 2022
Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022 PR Newswire Enrollment completed and dosing resumed in the ongoing Phase 2 REVIVE study Resumption of rusfertide administration after suspensi...
Gainers: Protagonist Therapeutics (PTGX) +10%. Marriott International (MAR) +7%. Aurora Innovation (AUR) +6%. MannKind Corporation (MNKD) +5%. Arcimoto (FUV) +5%. Losers: Enanta Pharmaceuticals (ENTA) -15%. Cisco Systems (CSCO) -12%. Limelight Networks (LLNW) -5%. Copart (CPRT) -4%....
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...